Brokerages expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to post earnings per share (EPS) of $0.93 for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for IDEXX Laboratories’ earnings, with the highest EPS estimate coming in at $0.99 and the lowest estimate coming in at $0.89. IDEXX Laboratories reported earnings per share of $0.65 during the same quarter last year, which would suggest a positive year-over-year growth rate of 43.1%. The firm is expected to announce its next earnings report on Friday, April 27th.
According to Zacks, analysts expect that IDEXX Laboratories will report full-year earnings of $4.11 per share for the current financial year, with EPS estimates ranging from $4.04 to $4.21. For the next year, analysts expect that the company will post earnings of $4.87 per share, with EPS estimates ranging from $4.75 to $5.03. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.04. The firm had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.58 earnings per share.
IDXX has been the subject of a number of research analyst reports. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price for the company in a research report on Monday, February 5th. BidaskClub downgraded IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America upped their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies upped their target price on IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $210.00 target price on shares of IDEXX Laboratories in a research report on Monday, January 29th. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $194.00.
IDEXX Laboratories (IDXX) traded up $1.36 on Friday, reaching $204.73. The company’s stock had a trading volume of 780,544 shares, compared to its average volume of 591,264. The firm has a market capitalization of $17,736.46, a P/E ratio of 69.64, a price-to-earnings-growth ratio of 2.50 and a beta of 0.58. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. IDEXX Laboratories has a 12-month low of $146.09 and a 12-month high of $207.14.
In other IDEXX Laboratories news, Director Daniel M. Junius sold 2,974 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $190.06, for a total value of $565,238.44. Following the transaction, the director now owns 5,602 shares of the company’s stock, valued at $1,064,716.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Brian P. Mckeon sold 6,602 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the completion of the transaction, the vice president now directly owns 47,040 shares in the company, valued at approximately $8,531,174.40. The disclosure for this sale can be found here. Insiders sold 91,736 shares of company stock worth $16,193,502 in the last ninety days. 2.77% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Zions Bancorporation bought a new position in shares of IDEXX Laboratories in the third quarter valued at $162,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of IDEXX Laboratories by 1,000.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after buying an additional 1,000 shares in the last quarter. SignalPoint Asset Management LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at $200,000. Ledyard National Bank increased its holdings in shares of IDEXX Laboratories by 58.9% in the fourth quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock valued at $203,000 after buying an additional 480 shares in the last quarter. Finally, Unio Capital LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at $203,000. 87.09% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/03/16/0-93-earnings-per-share-expected-for-idexx-laboratories-inc-idxx-this-quarter.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Get a free copy of the Zacks research report on IDEXX Laboratories (IDXX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.